Akero's Net Loss Widens Amid Escalating R&D for EFX

TL;DR

**Akero's burning cash fast on EFX trials; expect more losses before any potential win.**

AI Summary

Akero Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the three months ended June 30, 2025, was $65.4 million, an increase from $58.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $130.1 million, up from $110.2 million in 2024. Research and development expenses increased to $55.7 million for the three months ended June 30, 2025, from $49.5 million in 2024, primarily due to increased clinical trial activities for efruxifermin (EFX). General and administrative expenses rose to $10.1 million from $9.0 million in the comparable 2024 period. The company's cash, cash equivalents, and marketable securities totaled $450.0 million as of June 30, 2025, compared to $580.0 million as of December 31, 2024, indicating a significant burn rate. Akero continues to focus on the development of EFX for metabolic diseases, with ongoing clinical trials driving increased expenditures.

Why It Matters

Akero's increasing net losses and R&D expenditures highlight the high-stakes nature of clinical-stage biotechnology. For investors, the significant cash burn, with cash reserves dropping by $130 million in six months, signals a potential need for future financing if clinical milestones are delayed or unsuccessful. Employees and customers are directly impacted by the success or failure of EFX, Akero's lead candidate for metabolic diseases, which faces intense competition from larger pharmaceutical companies with deeper pockets. The broader market will watch Akero's progress as a bellwether for smaller biotechs developing treatments for widespread conditions like NASH, where a breakthrough could disrupt existing treatment paradigms.

Risk Assessment

Risk Level: high — The risk level is high due to Akero's significant and increasing net losses, reaching $130.1 million for the first six months of 2025, and its complete reliance on a single clinical-stage asset, efruxifermin (EFX), with no current revenue. The company's cash, cash equivalents, and marketable securities decreased by $130.0 million from $580.0 million at December 31, 2024, to $450.0 million at June 30, 2025, indicating a substantial burn rate that could necessitate future dilutive financing.

Analyst Insight

Investors should closely monitor Akero's clinical trial progress for efruxifermin (EFX) and its cash runway. Given the high burn rate and lack of revenue, consider the potential for future equity offerings and the associated dilution before making investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$65.4M

eps

N/A

gross Margin

N/A

cash Position

$450.0M

revenue Growth

N/A

Key Numbers

• $65.4M — Net Loss (Q2 2025) (Increased from $58.1M in Q2 2024)
• $130.1M — Net Loss (YTD Q2 2025) (Increased from $110.2M in YTD Q2 2024)
• $55.7M — R&D Expenses (Q2 2025) (Increased from $49.5M in Q2 2024 due to EFX trials)
• $450.0M — Cash, Cash Equivalents, and Marketable Securities (June 30, 2025) (Decreased from $580.0M at December 31, 2024)
• $10.1M — G&A Expenses (Q2 2025) (Increased from $9.0M in Q2 2024)

Key Players & Entities

• Akero Therapeutics, Inc. (company) — filer of the 10-Q
• efruxifermin (EFX) (company) — lead clinical candidate
• Hercules Capital, Inc. (company) — lender in Loan and Security Agreement
• SEC (regulator) — recipient of the 10-Q filing
• Bloomberg (company) — publisher of this analysis

FAQ

Risk Factors

• Significant Cash Burn Rate [high — financial]: Akero Therapeutics reported a substantial net loss of $65.4 million for Q2 2025, an increase from $58.1 million in Q2 2024. The company's cash, cash equivalents, and marketable securities decreased to $450.0 million as of June 30, 2025, from $580.0 million at the end of 2024. This trend indicates a significant burn rate, raising concerns about the company's ability to fund ongoing operations and clinical trials without additional capital.
• Dependence on Clinical Trial Success [high — operational]: As a clinical-stage company, Akero's primary focus is the development of efruxifermin (EFX). The increase in R&D expenses to $55.7 million in Q2 2025, driven by clinical trial activities, highlights the company's heavy reliance on the successful progression and outcome of these trials. Any delays, setbacks, or negative results could significantly impact future development and financial performance.
• Regulatory Approval Pathway [medium — regulatory]: Akero is developing EFX for metabolic diseases, a field with stringent regulatory requirements. The company must navigate the complex and lengthy process of clinical trials, data submission, and review by regulatory bodies like the FDA. Failure to meet regulatory standards or obtain necessary approvals could halt product development and commercialization efforts.
• Limited Revenue Generation [medium — financial]: The company reported no revenue for the three and six months ended June 30, 2025, which is typical for a clinical-stage biopharmaceutical company. However, this lack of revenue means Akero is entirely dependent on its existing cash reserves and potential future financing to fund its operations and development pipeline. The absence of revenue streams poses a long-term financial risk.

Industry Context

Akero Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on metabolic diseases. The sector is characterized by long development cycles, significant R&D investment, and high failure rates. Companies like Akero are driven by innovation and the pursuit of novel therapies, often relying on external funding until a product reaches commercialization.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Akero faces significant regulatory hurdles. The development and approval of efruxifermin (EFX) are subject to rigorous review by health authorities such as the FDA. Any delays or failures in clinical trials or the approval process could severely impact the company's prospects and financial standing.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for EFX.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the competitive landscape for metabolic disease treatments.

Glossary

Clinical-stage

A company that is in the process of testing its drug candidates in human clinical trials to determine safety and efficacy, but has not yet received regulatory approval for marketing. (Indicates Akero Therapeutics has no revenue-generating products and relies heavily on R&D investment and future approvals.)

Efruxifermin (EFX)

Akero Therapeutics' lead product candidate, a novel Fc-FGF21 fusion protein designed to treat metabolic diseases. (This is the primary asset driving the company's research and development expenses and future revenue potential.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Highlights the company's current financial performance, showing significant operational costs without corresponding revenue.)

Cash, Cash Equivalents, and Marketable Securities

The total liquid assets a company has readily available to fund its operations, investments, and other financial obligations. (Represents the company's financial runway and its ability to continue operations and fund its development pipeline.)

Research and Development (R&D) Expenses

Costs incurred by a company in the process of developing new products or improving existing ones, particularly relevant in the pharmaceutical and biotech industries. (Shows the significant investment Akero is making in its drug development pipeline, specifically for EFX.)

General and Administrative (G&A) Expenses

Costs associated with the overall management and operation of a business, not directly tied to product development or sales. (Indicates the overhead costs of running the company, which have also seen an increase.)

Year-Over-Year Comparison

Compared to the prior year period, Akero Therapeutics has seen an increase in its net loss, with Q2 2025 losses at $65.4 million versus $58.1 million in Q2 2024. This widening loss is primarily driven by increased Research and Development expenses, which rose to $55.7 million from $49.5 million, reflecting intensified clinical trial activities for efruxifermin. General and administrative expenses also saw a modest increase. The company's cash position has decreased from $580.0 million at the end of 2024 to $450.0 million as of June 30, 2025, indicating a higher operational expenditure rate.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AKRO The Nasdaq Global Se

Filing Documents

• akro-20250630.htm (10-Q) — 3171KB
• akro-ex10_1.htm (EX-10.1) — 34KB
• akro-ex31_1.htm (EX-31.1) — 18KB
• akro-ex31_2.htm (EX-31.2) — 17KB
• akro-ex32_1.htm (EX-32.1) — 16KB
• 0001193125-25-176038.txt ( ) — 11561KB
• akro-20250630.xsd (EX-101.SCH) — 1318KB
• akro-20250630_htm.xml (XML) — 2306KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3 .

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 90 Item 3. Defaults Upon Senior Securities 90 Item 4. Mine Safety Disclosures 90 Item 5. Other Information 90 Item 6. Exhibits 91

Signatures

Signatures 92 4 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: the success, cost and timing of our product development activities and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; our ability to successfully enroll, conduct and complete the three parallel, randomized, placebo-controlled, global clinical trials of our Phase 3 SYNCHRONY program, including our ability to reach agreement with the FDA and other regulatory authorities on clinical trial designs the impact of geopolitical tensio

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements Akero Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 220,449 $ 340,238 Short-term marketable securities 521,866 402,840 Prepaid expenses and other current assets 22,285 27,302 Total current assets 764,600 770,380 Long-term marketable securities 343,931 54,751 Right of use asset 621 755 Total assets $ 1,109,152 $ 825,886 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 13,249 $ 9,027 Accrued expenses and other current liabilities 33,651 30,727 Loan payable, current 13,501 — Total current liabilities 60,401 39,754 Loan payable, noncurrent 22,160 35,297 Warrant liability 400 194 Operating lease liability, noncurrent 372 529 Total liabilities 83,333 75,774 Commitments and contingencies (Note 12) Stockholders' equity: Common stock, $ 0.0001 par value, 150,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 79,919,203 and 72,383,013 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 8 7 Additional paid-in capital 1,992,209 1,575,313 Accumulated other comprehensive income 988 948 Accumulated deficit ( 967,386 ) ( 826,156 ) Total stockholders' equity 1,025,819 750,112 Total liabilities and stockholders' equity $ 1,109,152 $ 825,886 The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents Akero Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses:

View Full Filing

View this 10-Q filing on SEC EDGAR